Business
Enlaza Therapeutics Announces Strategic Collaboration with Vertex Pharmaceuticals to Develop War-Lock Drug Conjugates and T-Cell Engagers for Improved Conditioning and Certain Autoimmune Diseases
LA JOLLA, Calif., September 02, 2025--Enlaza Therapeutics Announces Strategic Collaboration with Vertex Pharmaceuticals
About this update from Vertex Pharmaceuticals Incorporated
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":221,"url":"https://media.zenfs.com/en/business-wire.com/05897a27b5d4a3514b8d5aa21ac571b1"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/EzzZK0JOE7sm0fO4VTVY8w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ0MjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/05897a27b5d4a3514b8d5aa21ac571b1","width":480,"height":221}},"lazy":false},{"type":"text","content":"LA JOLLA, Calif., September 02, 2025--(BUSINESS WIRE)--Enlaza Therapeutics ("Enlaza" or the "Company"), the first covalent biologics platform company, today announced a multi-target drug discovery collaboration with Vertex Pharmaceuticals ("Vertex") (Nasdaq: VRTX) to utilize Enlaza’s proprietary War-Lock™ technology platform to develop small format drug conjugates and T-cell engagers for certain autoimmune diseases and improved conditioning in sickle cell disease and beta thalassemia.","length":519,"tagName":"p"},{"type":"text","content":"Enlaza’s War-Lock platform creates highly specific warheads that covalently bind to drug targets of interest. This white-space technology enables a covalent-acting protein drug that retains the selectivity of small format biologics. The Company’s novel platform utilizes proprietary non-natural amino acids to precision-engineer biologic medicines that expand the therapeutic window to enable safer, more effective therapies across numerous therapeutic modalities.","length":464,"tagName":"p"},{"type":"text","content":""Our proprietary covalent biologics platform has demonstrated compelling promise in oncology, and this strategic collaboration marks a key inflection point as we expand into autoimmune indications," said Sergio Duron, Ph.D., CEO of Enlaza Therapeutics. "By partnering with Vertex, a proven leader in bringing first-in-class and/or best-in-class medicines to patients, we gain a valued partner to help unlock the potential of covalent protein drugs, opening new markets and accelerating development of differentiated biologics with best-in-class potential."","length":576,"tagName":"p"},{"type":"text","content":""Vertex is committed to developing transformative therapies for serious diseases that fit within our unique R&D strategy includi...